​

Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JAZZ Stock Forecast

Jazz Pharmaceuticals (JAZZ) stock forecast, based on 47 Wall Street analysts, predicts a 12-month average price target of $190.43, with a high of $219.00 and a low of $152.00. This represents a 15.48% increase from the last price of $164.90.

$100 $130 $160 $190 $220 $250 High: $219 Avg: $190.43 Low: $152 Last Closed Price: $164.9

JAZZ Stock Rating

Jazz Pharmaceuticals stock's rating consensus is Buy, based on 47 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 41 Buy (87.23%), 6 Hold (12.77%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 47 0 6 41 Strong Sell Sell Hold Buy Strong Buy

JAZZ Price Target Upside V Benchmarks

TypeNameUpside
StockJazz Pharmaceuticals15.48%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%
IdeaCannabis Stocks List49.75%

Price Target Trends

1M3M12M
# Anlaysts4713
Avg Price Target$201.50$191.29$187.69
Last Closing Price$164.90$164.90$164.90
Upside/Downside22.20%16.00%13.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 254103--17
Nov, 256111--18
Oct, 256111--18
Sep, 256111--18
Aug, 256111--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025David AmsellemPiper Sandler$219.00$162.2634.97%32.81%
Nov 24, 2025Ashwani VermaUBS$188.00$176.936.26%14.01%
Nov 17, 2025RBC Capital$194.00$170.1414.02%17.65%
Nov 17, 2025Sean LaamanMorgan Stanley$205.00$170.1620.47%24.32%
Oct 24, 2025Morgan Stanley$183.00$137.9732.64%10.98%
Oct 22, 2025Wells Fargo$170.00$137.5023.64%3.09%
Oct 20, 2025Morgan Stanley$180.00$137.0731.32%9.16%
Aug 28, 2025Joon LeeTruist Financial$205.00$124.8764.17%24.32%
Aug 28, 2025Gregory RenzaRBC Capital$151.00$124.3621.42%-8.43%
Jul 15, 2025David HoangDeutsche Bank$152.00$112.3035.35%-7.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025Piper SandlerOverweightOverweighthold
Nov 24, 2025UBSBuyNeutraldowngrade
Nov 17, 2025RBC CapitalOutperformOutperformhold
Nov 17, 2025Morgan StanleyOverweightOverweighthold
Oct 20, 2025Morgan StanleyOverweightOverweighthold
Sep 24, 2025Morgan StanleyOverweightOverweighthold
Aug 28, 2025RBC CapitalOutperformOutperformhold
Aug 28, 2025Morgan StanleyOverweightOverweighthold
Jul 15, 2025Deutsche BankBuyinitialise
Mar 07, 2025UBSUnderperformBuyupgrade

Financial Forecast

EPS Forecast

$-10 $-1 $8 $17 $26 $35 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.28$-5.51$-3.42$6.95$9.06----
Avg Forecast$12.60$15.67$13.56$18.50$20.21$21.88$22.40$25.00$26.78
High Forecast$13.20$16.42$14.21$18.73$20.49$23.81$26.66$31.99$28.52
Low Forecast$11.91$14.81$12.76$18.16$19.74$19.59$16.18$14.90$25.04
Surprise %-66.03%-135.16%-125.22%-62.43%-55.17%----

Revenue Forecast

$2B $3B $3B $4B $5B $6B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.36B$3.09B$3.66B$3.83B$4.07B----
Avg Forecast$2.33B$3.06B$3.66B$3.83B$4.04B$4.31B$4.48B$4.76B$5.04B
High Forecast$2.42B$3.18B$3.79B$3.93B$4.06B$4.53B$4.49B$4.78B$5.30B
Low Forecast$2.23B$2.93B$3.49B$3.78B$4.01B$4.10B$4.46B$4.73B$4.79B
Surprise %1.37%1.04%0.00%0.02%0.76%----

Net Income Forecast

$-500M $100M $700M $1B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$238.62M$-328.95M$-214.14M$414.83M$560.12M----
Avg Forecast$162.64M$1.13B$177.38M$414.83M$1.45B$1.56B$1.54B$1.69B$1.93B
High Forecast$279.03M$1.18B$226.81M$530.42M$1.48B$1.72B$1.92B$2.31B$2.06B
Low Forecast$46.25M$1.07B$127.96M$299.25M$1.42B$1.41B$1.17B$1.07B$1.80B
Surprise %46.72%-129.13%-220.72%--61.36%----

JAZZ Forecast FAQ

Is Jazz Pharmaceuticals stock a buy?

Jazz Pharmaceuticals stock has a consensus rating of Buy, based on 47 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 41 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jazz Pharmaceuticals is a favorable investment for most analysts.

What is Jazz Pharmaceuticals's price target?

Jazz Pharmaceuticals's price target, set by 47 Wall Street analysts, averages $190.43 over the next 12 months. The price target range spans from $152 at the low end to $219 at the high end, suggesting a potential 15.48% change from the previous closing price of $164.9.

How does Jazz Pharmaceuticals stock forecast compare to its benchmarks?

Jazz Pharmaceuticals's stock forecast shows a 15.48% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%), trailing the Cannabis Stocks List (49.75%) investment idea.

What is the breakdown of analyst ratings for Jazz Pharmaceuticals over the past three months?

  • December 2025: 23.53% Strong Buy, 58.82% Buy, 17.65% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 33.33% Strong Buy, 61.11% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 33.33% Strong Buy, 61.11% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.

What is Jazz Pharmaceuticals’s EPS forecast?

Jazz Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $21.88, marking a 141.50% increase from the reported $9.06 in 2024. Estimates for the following years are $22.4 in 2026, $25 in 2027, and $26.78 in 2028.

What is Jazz Pharmaceuticals’s revenue forecast?

Jazz Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $4.31B, reflecting a 5.92% increase from the reported $4.07B in 2024. The forecast for 2026 is $4.48B, followed by $4.76B for 2027, and $5.04B for 2028.

What is Jazz Pharmaceuticals’s net income forecast?

Jazz Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $1.56B, representing an 179.23% increase from the reported $560.12M in 2024. Projections indicate $1.54B in 2026, $1.69B in 2027, and $1.93B in 2028.